Pharmaxis Ltd (AU:SNT) has released an update. Syntara Limited’s interim results from its Phase 2 trial for the myelofibrosis treatment ...
President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...
At this time, I would like to welcome everyone to Karyopharm Therapeutics third quarter 2024 financial results conference ...
MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
The Company's partner, Incyte, is now recruiting patients for a Phase 2, open-label, randomized, multicenter trial of axatilimab in combination with ruxolitinib in patients ≥12 years of age with newly ...
The full abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical ...
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...
Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback